Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Expert
Prof. Diamant Thaçi, University of Lübeck, Germany
Conference
EADV 2019

A head-to-head comparison of the selective IL-23 blocker risankizumab with oral fumaric acid esters in treatment-naïve patients with moderate-to-severe psoriasis demonstrated superiority of the biologic in all assessed efficacy endpoints at week 24 [1].

In the Netherlands, Germany, the United Kingdom, and Ireland, fumaric acid esters are frequently used for systemic therapy of moderate-to-severe psoriasis [2-4]. A new head-to-head trial included systemic treatment-naïve adult patients with chronic moderate-to-severe plaque psoriasis of at least 6 months duration. All patients qualified for systemic therapy: they had a psoriasis area and severity index score >10, an affected body surface area of >10%, and their quality of life was severely impaired (dermatology life quality index score of >10). Patients were randomised to receive subcutaneous risankizumab 150 mg at weeks 0, 4, and 16 (n=60) or oral fumaric acid esters in increasing doses from week ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on